August 3rd, 2010
Building on Your Success
Harlan M. Krumholz, MD, SM
Welcome to the remodeled CardioExchange: We hope you like our new look! In our efforts to develop a website that promotes learning and discussion about our rapidly evolving field, we’ve been listening and learning.
We have many new features. Some of the most prominent are:
- You can now see all of the activity on the site from the new homepage, including newly uploaded posts and comments.
- You can now make anonymous comments. Many people think this may foster more discussion. We are eager to see whether that happens.
- You can now “follow” the people, blogs, and topics that interest you the most and receive email notifications when new activity takes place.
With all these changes, our philosophy and approach remain the same. We want to be a credible, trustworthy source of information and a venue for the exchange of views and perspectives. We want to give you access to the various ways people are thinking about new (and old) information in medicine — and provide you the opportunity to learn from each other.
And we are not done listening. We will continue to learn from what you say on and do with CardioExchange, as well as from your direct feedback. Ultimately, the site is a facilitator; it is the people who make CardioExchange. We will be encouraging you to be more involved and to try out the various features. And we ask you to bring in others to participate. The site ultimately belongs to the community — and it is up to all of us to define it.
Categories: General
Tags: CardioExchange, social media
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Mineralocorticoid Receptor Antagonism — FINDing Another Benefit August 6, 2026Aldosterone plays a critical role in the homeostasis of blood pressure and volume by engaging mineralocorticoid receptors in the kidneys, heart, and other organs.1 However, overactivation of mineralocorticoid receptors contributes to the pathogenesis of chronic kidney disease (CKD) and heart failure, in part by causing inflammation and fibrosis....
- Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD August 6, 2026In a patient with Duchenne muscular dystrophy, cardiotoxic effects developed after treatment with delandistrogene moxeparvovec. Microdystrophin levels in the heart and skeletal muscle were less than 1% of normal dystrophin levels.
- Obstructive Hypertrophic Cardiomyopathy August 6, 2026A 31-year-old man was evaluated for an abnormal ECG. Echocardiography revealed marked ventricular hypertrophy. Subsequent imaging (shown in a video) showed near-complete apposition of the ventricular walls during systole.
- Oxygen Targets after Cardiac Arrest — A LOGICAL Finding August 6, 2026In unresponsive patients after cardiac arrest, a complex pathophysiological response including potential brain injury, myocardial dysfunction, and systemic ischemia–reperfusion injury is at play, in addition to the challenges of the underlying cause of cardiac arrest.1 This complex and unique, but heterogeneous, constellation has prompted clinicians and researchers to...
- Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease August 6, 2026Patients with advanced peripheral artery disease often undergo either surgical or endovascular revascularization for the treatment of lifestyle-limiting claudication or nonhealing lower-limb wounds. Major limitations of endovascular intervention include the high incidence of restenosis and the need for repeat intervention with standard balloon angioplasty. During the past decade, the use...
- Mineralocorticoid Receptor Antagonism — FINDing Another Benefit August 6, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
